Patents Examined by Venkataraman Balasubramanian
  • Patent number: 10316023
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 11, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor
  • Patent number: 10316024
    Abstract: Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): wherein at least one of R1a to R9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): wherein R10a to R12a each represent a divalent hydrocarbon group or the like; and R13a represents a monovalent hydrocarbon group or the like.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 11, 2019
    Assignees: MIYOSHI OIL & FAT CO., LTD., TOKAI OPTICAL CO., LTD.
    Inventors: Koji Kawai, Kotaro Kaneko, Nobuhiro Kaneko, Yuichi Shishino, Kuniyoshi Okamoto
  • Patent number: 10308634
    Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 4, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
  • Patent number: 10301263
    Abstract: The invention relates to pharmaceutical uses of compounds of formula (II). Particular aspects of the invention relate to the use of those compounds in treating, preventing or ameliorating a seizure-related disorder, bipolar disorder, mania, migraine, Alzheimer's disease, Parkinson's disease or stroke.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: May 28, 2019
    Assignee: Royal Holloway and Bedford New College
    Inventors: Robin Williams, Matthew Walker
  • Patent number: 10300064
    Abstract: The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: May 28, 2019
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Gretchen Snyder, Lawrence P. Wennogle, Joseph Hendrick
  • Patent number: 10297768
    Abstract: Disclosed herein are multidentate dinuclear cyclometallated complexes. The complexes are suitable as emitting materials or host materials in OLED devices.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: May 21, 2019
    Assignees: ZHEJIANG UNIVERSITY OF TECHNOLOGY, AAC MICROTECH (CHANGZHOU) CO., LTD.
    Inventors: Guijie Li, Yuanbin She, Xiangdong Zhao, Shaohai Chen
  • Patent number: 10294249
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 21, 2019
    Assignee: Qpex Biopharma, Inc.
    Inventors: Scott J. Hecker, Raja K. Reddy, Tomasz Glinka, Olga Rodny
  • Patent number: 10287291
    Abstract: seco-Cyclopropapyrroloindole compounds of formula (I) where Hal, R1, R2, and R3 are as defined in the application, are potent anti-cancer agents that can be used in antibody-drug conjugates.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 14, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fukang Yang, Qian Zhang, Lawrence B. Snyder, Sanjeev Gangwar, Dale L. Boger
  • Patent number: 10280170
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: May 7, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Meerpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • Patent number: 10280156
    Abstract: The present invention relates to heteroaromatic chalcone derivatives, particularly the compounds of formula (I) as described and defined herein, pharmaceutical compositions comprising these compounds, and their medical use, including their use in the treatment or prevention of cancer and, in particular, in the treatment or prevention of hematologic malignancies.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 7, 2019
    Assignees: Medizinische Universität Wien, Universität Wien
    Inventors: Katrina Vanura, Ulrich Jäger, Thomas Erker, Gerda Brunhofer-Bolzer
  • Patent number: 10280153
    Abstract: Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: May 7, 2019
    Assignee: F.I.S.—Fabbrica Italiana Sintetici S.p.A.
    Inventors: JinPu Shi, Roberto Profeta
  • Patent number: 10280183
    Abstract: The present disclosure relates to a therapeutic agent of the formula: Z—C(?O)—(CH2)n-?-S—S—(CRR?)m-(CH2)p-C(?O)—NH—(CH2)q-NH—Y[NH—(CH2)r-X-T-W][NH—(CH2—CH—O)t(CH2)s-NH—V]??Formula I or a pharmaceutically acceptable salt thereof, useful for treating tumors, including cancers. Where the compound of Formula I also contains a radionuclide or an imaging agent or both, the compound of formula I is a theranostic agent useful for treating and diagnosing tumors, including cancers.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: May 7, 2019
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Jacob Vineberg, Tao Wang
  • Patent number: 10276804
    Abstract: The present invention relates to a compound for an organic optoelectronic element represented by Chemical Formula 1, an element comprising the same, and a display device comprising the organic optoelectronic element (details of Chemical Formula 1 are as described in the specification).
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 30, 2019
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Seung-Jae Lee, Dong-Min Kang, Eun-Sun Yu, Sang-Shin Lee, Sung-Hyun Jung, Ho-Kuk Jung, Su-Jin Han
  • Patent number: 10276802
    Abstract: Example embodiments provide a compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: April 30, 2019
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Hiromasa Shibuya, Tatsuya Imase, Rie Sakurai, Xavier Bulliard, Hyesung Choi, Tadao Yagi, Sung Young Yun, Gae Hwang Lee, Kwang Hee Lee, Dong-Seok Leem, Yeong Suk Choi
  • Patent number: 10259808
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: April 16, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Emanuela Gancia, Tammy Ladduwahetty, David Vesey, Paul Winship, Olivier Rene
  • Patent number: 10258598
    Abstract: The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 16, 2019
    Assignees: Semmelweis University, Fujimoto Co. Ltd.
    Inventors: József Knoll, Ildikó Miklya, Péter Ferdinandy, Dezso Schuler, Zsuzsanna Schaff, Sándor Eckhardt
  • Patent number: 10259814
    Abstract: This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: April 16, 2019
    Assignee: Janssen Sciences Ireland UC
    Inventors: David Craig McGowan, Stefaan Julien Last, Serge Maria Aloysius Pieters, Werner Embrechts, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10259826
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 16, 2019
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Ankush Argade, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim
  • Patent number: 10256427
    Abstract: An OLED device includes, in order, an electron blocking layer, an organic emissive layer, and a hole blocking layer. Its organic emissive layer contains at least four components: an electron transporting compound, a host, a hole transporting compound, and an emitting compound capable of phosphorescence emission at room temperature. The emitting compound has HOMO energy level of 5.2 eV or lower and a LUMO energy level of 2.5 eV or higher.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: April 9, 2019
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Vadim Adamovich, James Esler, Jason Brooks, Michael S. Weaver, Julia J. Brown
  • Patent number: 10246446
    Abstract: Compounds and methods for treating diseases or conditions affected by the activity or expression of genes/proteins related to human GH, GHR, STAT5, SOCS, IGF-1, insulin are provided. Monoclonal antibodies for treating diseases or conditions related to growth hormone and growth hormone receptor activity are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: April 2, 2019
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Priya Balasubramanian, Nouri Neamati, Min Wei